{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:09:12Z","timestamp":1794236952927,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA219541"],"award-info":[{"award-number":["CA219541"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA226281"],"award-info":[{"award-number":["CA226281"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>RNA N6-Methyladenosine (m6A) modification is implicated in the progression of human cancers including cholangiocarcinoma (CCA). METTL16 is recently identified as a new RNA methyltransferase responsible for m6A modification, although the role of METTL16 in CCA has not yet been examined. The current study aims to investigate the effect and mechanism of the RNA methyltransferase METTL16 in CCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of METTL16 in CCA was examined by analyzing publicly available datasets or by IHC staining on tumor samples. siRNA or CRISPR\/Cas9-mediated loss of function studies were performed in vitro and in vivo to investigate the oncogenic role of METTL16 in CCA. MeRIP-Seq was carried out to identify the downstream target of METTL16. ChIP-qPCR, immunoprecipitation, and immunoblots were used to explore the regulation mechanisms for METTL16 expression in CCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed that the expression of METTL16 was noticeably increased in human CCA tissues. Depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression. PRDM15 was identified as a key target of METTL16 in CCA cells. Mechanistically, our data showed that METTL16 regulated PRDM15 protein expression via YTHDF1-dependent translation. Accordingly, we observed that restoration of PRDM15 expression could rescue the deficiency of CCA cell proliferation\/colony formation induced by METTL16 depletion. Our subsequent analyses revealed that METTL16-PRDM15 signaling regulated the expression of FGFR4 in CCA cells. Specifically, we observed that PRDM15 protein was associated with the FGFR4 promoter to regulate its expression. Furthermore, we showed that the histone acetyltransferase p300 cooperated with the transcription factor YY1 to regulate METTL16 gene expression via histone H3 lysine 27 (H3K27) acetylation in CCA cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study describes a novel METTL16-PRDM15-FGFR4 signaling axis which is crucial for CCA growth and may have important therapeutic implications. We showed that depletion of METTL16 significantly inhibited CCA cell proliferation and decreased tumor progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02844-5","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:28:36Z","timestamp":1696994916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression"],"prefix":"10.1186","volume":"42","author":[{"given":"Nianli","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2844_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2844_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65.","journal-title":"Nat Rev Dis Primers"},{"key":"2844_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021;73:75\u201385.","journal-title":"Hepatology"},{"key":"2844_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.31278","volume":"73","author":"CJ O\u2019Rourke","year":"2021","unstructured":"O\u2019Rourke CJ, Munoz-Garrido P, Andersen JB. Molecular targets in cholangiocarcinoma. Hepatology. 2021;73:62\u201374.","journal-title":"Hepatology"},{"key":"2844_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/hep.30289","volume":"69","author":"AE Sirica","year":"2019","unstructured":"Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803\u201315.","journal-title":"Hepatology"},{"key":"2844_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","volume":"273","author":"WA Cambridge","year":"2021","unstructured":"Cambridge WA, Fairfield C, Powell JJ, Harrison EM, S\u00f8reide K, Wigmore SJ, Guest RV. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma. Ann Surg. 2021;273:240\u201350.","journal-title":"Ann Surg"},{"key":"2844_CR7","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, Zhao X, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.","journal-title":"Nat Commun"},{"key":"2844_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003\u201310.","journal-title":"Nat Genet"},{"key":"2844_CR9","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, et al. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2022;12:1378\u201395.","journal-title":"Cancer Discov"},{"key":"2844_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2014.02.050","volume":"446","author":"YF Xu","year":"2014","unstructured":"Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, Ning SL, et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun. 2014;446:54\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"2844_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/jgh.12916","volume":"30","author":"C Ang","year":"2015","unstructured":"Ang C. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. J Gastroenterol Hepatol. 2015;30:1116\u201322.","journal-title":"J Gastroenterol Hepatol"},{"key":"2844_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020;37:270\u201388.","journal-title":"Cancer Cell"},{"key":"2844_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","volume":"86","author":"W Li","year":"2022","unstructured":"Li W, Deng X, Chen J. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 2022;86:664\u201377.","journal-title":"Semin Cancer Biol."},{"key":"2844_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, et al. A METTL3\u2013METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u20135.","journal-title":"Nat Chem Biol"},{"key":"2844_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306\u201317.","journal-title":"Mol Cell"},{"key":"2844_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gong Z, et al. Structural basis of N 6-adenosine methylation by the METTL3\u2013METTL14 complex. Nature. 2016;534:575\u20138.","journal-title":"Nature"},{"key":"2844_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.celrep.2014.05.048","volume":"8","author":"S Schwartz","year":"2014","unstructured":"Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5\u2032 sites. Cell Rep. 2014;8:284\u201396.","journal-title":"Cell Rep"},{"key":"2844_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41556-021-00835-2","volume":"24","author":"R Su","year":"2022","unstructured":"Su R, Dong L, Li Y, Gao M, He PC, Liu W, Wei J, et al. METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis. Nat Cell Biol. 2022;24:205\u201316.","journal-title":"Nat Cell Biol"},{"key":"2844_CR19","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.15252\/embr.201744940","volume":"18","author":"AS Warda","year":"2017","unstructured":"Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, H\u00f6bartner C, Sloan KE, et al. Human METTL16 is a N6-methyladenosine (m6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017;18:2004\u201314.","journal-title":"EMBO Rep"},{"issue":"824\u2013835","key":"2844_CR20","first-page":"e814","volume":"169","author":"KE Pendleton","year":"2017","unstructured":"Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, Conrad NK. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(824\u2013835):e814.","journal-title":"Cell"},{"issue":"986\u20131000","key":"2844_CR21","first-page":"e1011","volume":"71","author":"M Mendel","year":"2018","unstructured":"Mendel M, Chen K-M, Homolka D, Gos P, Pandey RR, McCarthy AA, Pillai RS. Methylation of structured RNA by the m6A writer METTL16 is essential for mouse embryonic development. Mol Cell. 2018;71(986\u20131000):e1011.","journal-title":"Mol Cell"},{"issue":"52\u201368","key":"2844_CR22","first-page":"e13","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, Chen Z, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30(52\u201368):e13.","journal-title":"Cell Stem Cell"},{"key":"2844_CR23","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.1038\/s41467-022-34078-y","volume":"13","author":"M Yoshinaga","year":"2022","unstructured":"Yoshinaga M, Han K, Morgens DW, Horii T, Kobayashi R, Tsuruyama T, Hia F, et al. The N(6)-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity. Nat Commun. 2022;13:6435.","journal-title":"Nat Commun"},{"key":"2844_CR24","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1111\/jcmm.16664","volume":"25","author":"XK Wang","year":"2021","unstructured":"Wang XK, Zhang YW, Wang CM, Li B, Zhang TZ, Zhou WJ, Cheng Lj, et al. METTL16 promotes cell proliferation by up\u2010regulating cyclin D1 expression in gastric cancer. J Cell Mol Med. 2021;25:6602\u201317.","journal-title":"J Cell Mol Med"},{"key":"2844_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s11658-022-00342-8","volume":"27","author":"YZ Dai","year":"2022","unstructured":"Dai YZ, Liu YD, Li J, Chen MT, Huang M, Wang F, Yang QS, et al. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner. Cell Mol Biol Lett. 2022;27:41.","journal-title":"Cell Mol Biol Lett"},{"key":"2844_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2022.10.065","volume":"638","author":"F Ye","year":"2022","unstructured":"Ye F, Wu J, Zhang F. METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis. Biochem Biophys Res Commun. 2022;638:1\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"2844_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s43018-022-00429-3","volume":"3","author":"X Zeng","year":"2022","unstructured":"Zeng X, Zhao F, Cui G, Zhang Y, Deshpande RA, Chen Y, Deng M, et al. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Nat Cancer. 2022;3:1088\u2013104.","journal-title":"Nat Cancer"},{"key":"2844_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.31083\/j.fbl2806120","volume":"28","author":"F Wei","year":"2023","unstructured":"Wei F, Zhang JN, Zhao YQ, Lyu H, Chen F. Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma. Front Biosci (Landmark Ed). 2023;28:120.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2844_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/hep.31141","volume":"72","author":"W Ma","year":"2020","unstructured":"Ma W, Han C, Zhang J, Song K, Chen W, Kwon H, Wu T. The histone methyltransferase G9a promotes cholangiocarcinogenesis through regulation of the hippo pathway kinase LATS2 and YAP signaling pathway. Hepatology. 2020;72:1283\u201397.","journal-title":"Hepatology"},{"key":"2844_CR30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/cr.2017.117","volume":"27","author":"Z Lin","year":"2017","unstructured":"Lin Z, Hsu PJ, Xing X, Fang J, Lu Z, Zou Q, Zhang K-J, et al. Mettl3-\/Mettl14-mediated mRNA N6-methyladenosine modulates murine spermatogenesis. Cell Res. 2017;27:1216\u201330.","journal-title":"Cell Res"},{"key":"2844_CR31","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/ng.3922","volume":"49","author":"S Mzoughi","year":"2017","unstructured":"Mzoughi S, Zhang J, Hequet D, Teo SX, Fang H, Xing QR, Bezzi M, et al. PRDM15 safeguards naive pluripotency by transcriptionally regulating WNT and MAPK\u2013ERK signaling. Nat Genet. 2017;49:1354\u201363.","journal-title":"Nat Genet"},{"key":"2844_CR32","doi-asserted-by":"publisher","first-page":"16492","DOI":"10.1073\/pnas.2002672117","volume":"117","author":"E Manieri","year":"2020","unstructured":"Manieri E, Folgueira C, Rodriguez ME, Leiva-Vega L, Esteban-Lafuente L, Chen C, Cubero FJ, et al. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl Acad Sci U S A. 2020;117:16492\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2844_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jcb.30204","volume":"123","author":"AJ Phillips","year":"2022","unstructured":"Phillips AJ, Lobl MB, Hafeji YA, Safranek HR, Mohr AM, Mott JL. Glycosylation of FGFR4 in cholangiocarcinoma regulates receptor processing and cancer signaling. J Cell Biochem. 2022;123:568\u201380.","journal-title":"J Cell Biochem"},{"key":"2844_CR34","doi-asserted-by":"publisher","first-page":"e112012","DOI":"10.15252\/embj.2022112012","volume":"41","author":"M Wang","year":"2022","unstructured":"Wang M, Chen Z, Zhang Y. CBP\/p300 and HDAC activities regulate H3K27 acetylation dynamics and zygotic genome activation in mouse preimplantation embryos. EMBO J. 2022;41:e112012.","journal-title":"EMBO J"},{"key":"2844_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/0008-5472.CAN-20-1323","volume":"81","author":"L-Y Cai","year":"2021","unstructured":"Cai L-Y, Chen S-J, Xiao S-H, Sun Q-J, Ding C-H, Zheng B-N, Zhu X-Y, et al. Targeting p300\/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Can Res. 2021;81:860\u201372.","journal-title":"Can Res"},{"key":"2844_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bbagrm.2014.03.004","volume":"1839","author":"BK Kim","year":"2014","unstructured":"Kim BK, Im JY, Han G, Lee WJ, Won KJ, Chung KS, Lee K, et al. p300 cooperates with c-Jun and PARP-1 at the p300 binding site to activate RhoB transcription in NSC126188-mediated apoptosis. Biochim Biophys Acta Gene Regul Mech. 2014;1839:364\u201373.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"2844_CR37","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1535-7163.MCT-16-0185","volume":"15","author":"S Uttarkar","year":"2016","unstructured":"Uttarkar S, Piontek T, Dukare S, Schomburg C, Schlenke P, Berdel WE, Muller-Tidow C, et al. Small-Molecule Disruption of the Myb\/p300 Cooperation Targets Acute Myeloid Leukemia Cells. Mol Cancer Ther. 2016;15:2905\u201315.","journal-title":"Mol Cancer Ther"},{"key":"2844_CR38","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s41388-022-02185-1","volume":"41","author":"Q-C Xu","year":"2022","unstructured":"Xu Q-C, Tien Y-C, Shi Y-H, Chen S, Zhu Y-Q, Huang X-T, Huang C-S, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene. 2022;41:1622\u201333.","journal-title":"Oncogene"},{"key":"2844_CR39","first-page":"1","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma Z, Li C, Wang C, Jiang W, Chang J, Han S, et al. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. Nat Commun. 2022;13:1\u201313.","journal-title":"Nat Commun"},{"issue":"564\u2013576","key":"2844_CR40","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, et al. Defining a cancer dependency map. Cell. 2017;170(564\u2013576): e516.","journal-title":"Cell"},{"key":"2844_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2023.01.006","volume":"83","author":"E Sendinc","year":"2023","unstructured":"Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. Mol Cell. 2023;83:428\u201341.","journal-title":"Mol Cell"},{"key":"2844_CR42","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/febs.15844","volume":"289","author":"F Di Tullio","year":"2022","unstructured":"Di Tullio F, Schwarz M, Zorgati H, Mzoughi S, Guccione E. The duality of PRDM proteins: epigenetic and structural perspectives. FEBS J. 2022;289:1256\u201375.","journal-title":"FEBS J"},{"issue":"11","key":"2844_CR43","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41419-022-05402-7","volume":"13","author":"Y Yu","year":"2022","unstructured":"Yu Y, Liu TT, Yu GY, Wang H, Du ZP, Chen YY, Yang N, et al. PRDM15 interacts with DNA-PK-Ku complex to promote radioresistance in rectal cancer by facilitating DNA damage repair. Cell Death Dis. 2022;13(11):978.","journal-title":"Cell Death Dis."},{"key":"2844_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gde.2016.03.009","volume":"36","author":"S Mzoughi","year":"2016","unstructured":"Mzoughi S, Tan YX, Low D, Guccione E. The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev. 2016;36:83\u201391.","journal-title":"Curr Opin Genet Dev"},{"key":"2844_CR45","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.3390\/ijms19103250","volume":"19","author":"A Sorrentino","year":"2018","unstructured":"Sorrentino A, Federico A, Rienzo M, Gazzerro P, Bifulco M, Ciccodicola A, Casamassimi A, et al. PR\/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas. Int J Mol Sci. 2018;19:3250.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"2844_CR46","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1038\/s41467-020-17064-0","volume":"11","author":"S Mzoughi","year":"2020","unstructured":"Mzoughi S, Fong JY, Papadopoli D, Koh CM, Hulea L, Pigini P, Di Tullio F, et al. PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis. Nat Commun. 2020;11(1):3520.","journal-title":"Nat Commun."},{"key":"2844_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/jgh.15816","volume":"37","author":"X Huang","year":"2022","unstructured":"Huang X, Zhu L, Wang L, Huang W, Tan L, Liu H, Huo J, et al. YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation. J Gastroenterol Hepatol. 2022;37:1156\u201368.","journal-title":"J Gastroenterol Hepatol"},{"key":"2844_CR48","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of CholangiocarcinomaIntegrative Genomic and Epigenomic Analysis of Cholangiocarcinoma. Cancer Discov. 2017;7:1116\u201335.","journal-title":"Cancer Discov"},{"key":"2844_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ebiom.2019.11.021","volume":"50","author":"B Qiu","year":"2019","unstructured":"Qiu B, Chen T, Sun R, Liu Z, Zhang X, Li Z, Xu Y, et al. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle. EBioMedicine. 2019;50:166\u201377.","journal-title":"EBioMedicine"},{"key":"2844_CR50","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1074\/jbc.M115.698472","volume":"291","author":"S Rizvi","year":"2016","unstructured":"Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016;291:8031\u201347.","journal-title":"J Biol Chem"},{"key":"2844_CR51","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park J-W, Choo SP, et al. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaClinical Validation of FGF19 as a Driver of HCC. Cancer Discov. 2019;9:1696\u2013707.","journal-title":"Cancer Discov"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02844-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T03:22:42Z","timestamp":1700450562000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02844-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02844-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee of Tulane University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the authors are aware of the content of the study and consent to their inclusion as co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}